1. A medicament for the treatment of multiple sclerosis, characterized in that it is in the form of pharmaceutical compositions and includes activated-potentiated form of antibodies to brain-specific protein S-100.2. A medicament according to claim 1, characterized in that the activated-potentiated form of antibodies to brain-specific protein S-100 is used in the activated-potentiated form aqueous or aqueous-alcohol solution obtained in the process of successive dilutions of multiple respective matrix solution of antibodies in an aqueous or aqueous an alcohol solvent and an intermediate external mechanical impact - each razvedeniya.3 shaking. A medicament according to claim 1, characterized in that the pharmaceutical composition is in solid dosage form and comprises an effective amount of saturated activated-potentiated form of antibodies to brain-specific protein S-100 neutral carrier granules and pharmaceutically acceptable dobavki.4. A medicament according to claim 2, characterized in that the aqueous or aqueous-alcoholic solutions of the activated-potentiated forms of antibodies to brain-specific protein S-100 prepared by repeated successive dilution and intermediate external action of matrix solution affinity-purified antibodies to human gamma interferon and brain-specific S-100 protein with a concentration of 0.5 ÷ 5.0 mg / ml.5. A medicament according to claim 2, characterized in that each of the components in the form of activated-potentiated forms of antibodies to S-100 brain-specific proteins are used as a mixture of different,1. Лекарственное средство для лечения рассеянного склероза, характеризующееся тем, что выполнено в виде фармацевтической композиции и включает активированную-потенцированную форму антител к мозгоспецифическому белку S-100.2. Лекарственное средство по п.1, характеризующееся тем, что активированную-потенцированную форму антител к мозгоспецифическому белку S-100 используют в виде активированного-потенцированного водного или водно-спирто
